In an observational study of 48 patients with LAL-D4

81%

[39/48]

had reported LLM use

88%

[270/306]

of available LDL-c measurements ≥2.6 mmol/L

It is important to monitor disease progression in patients with LAL-D who are taking LLMs. In a case review of 27 patients with LAL-D on statins:1

56%

[15/27]

had liver biopsy findings showing fibrosis or cirrhosis

44%

[12/27]

underwent repeat biopsies, demonstrating progressive liver disease; of these, 50% (6/12) progressed to liver transplant or death
REGISTER TODAY

and receive all the latest LAL-D information.

*All fields are required

THANK YOU
Your registration on LALDSource.com ensures that you will be among the first to receive news and updates about LAL-D.